A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

Inclusion Criteria:

- Diagnosis of schizophrenia according to DSM-IV-TR criteria

- Has been able to achieve outpatient status for more than 3 months in the past year

- Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)

- Resides in a stable living situation

- Willing and able to be confined to an inpatient study unit for 2 weeks or longer

Exclusion Criteria:

- History of poor or inadequate clinical response to treatment with aripiprazole

- History of treatment resistance

- Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its
ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or
glycerol)

- Diagnosis of current substance dependence (including alcohol)

- Pregnant, lactating, or breastfeeding

- Receipt of any antipsychotic medication by IM injection within 60 days before
Screening

- Current involuntary hospitalization or incarceration

- Hospitalized for more than 30 days during the 90 days before Screening

Additional inclusion/exclusion criteria may apply.